Abstract:IntroductionThere are multiple antidiabetic drugs available in China, which vary in their efficacy and safety. However, no study exists that compares all the classes of antidiabetic drugs simultaneously. This study aimed to estimate and compare the efficacy of alternative classes of antidiabetic drugs for Chinese patients with type 2 diabetes, either in a monotherapy regimen or combined with metformin.MethodsA systematic literature review was conducted by searching various literature databases to identify relevant randomized controlled trials published from 1990 to 2016. A meta-analysis was conducted to compare the efficacy of antidiabetic drug monotherapy and placebo or lifestyle interventions (i.e., diet and exercise), and antidiabetic drug plus metformin versus metformin alone, in Chinese patients with type 2 diabetes. An indirect comparison was used to estimate the efficacy of antidiabetic drug plus metformin versus placebo or lifestyle-intervention using metformin as the common comparator.ResultsThe database search identified 354 relevant studies. Compared with placebo or lifestyle interventions, combination therapies achieved greater reductions in hemoglobin A1c (HbA1c) level (1.9% versus 0.9%), body mass index (BMI) (2.66 versus 0.98 kg/m2), and total cholesterol level (1.07 versus 0.35 mmol/L) than monotherapies. For monotherapies, the top three treatments for reducing HbA1c level were insulin, sulfonylurea, and glucagon-like peptide-1 (GLP-1) receptor agonist. The top three monotherapies for reducing BMI level were metformin, GLP-1 receptor agonist, and α-glycosidase inhibitor. The top three monotherapies for reducing total cholesterol level were metformin, GLP-1 receptor agonist, and dipeptidyl peptidase-4 (DPP-4) inhibitor. For combination therapies, the top three treatments for reducing HbA1c level were GLP-1 receptor agonist plus metformin, insulin plus metformin, and glinide plus metformin. The top three combination therapies for reducing BMI level were glinide plus metformin, GLP-1 receptor agonist plus metformin, and DPP-4 inhibitor plus metformin. The top three combination therapies for reducing total cholesterol level were insulin plus metformin, GLP-1 receptor agonist plus metformin, and α-glycosidase inhibitor plus metformin.ConclusionsPharmacological treatments had better efficacy than placebo or lifestyle interventions, while combination drug therapies were superior to monotherapies.

Contemporary Management of Type 2 Diabetes: A Basal-Bolus Approach ——China lecture tour of Professor VA Fonseca (Chief Editor of "Diabetes Care" )

Effect of Solution Focused Approach Model on Metabolic Parameters of Patients with T2DM

DING Xue-ping's clinical experience in treating obesity with hyperinsulinemia

Professor Ding Xueping's Experience in Treating Diabetes Mellitus

Professor Ding Xueping' S Experience in Differentiating and Treating Diabetes Mellitus with Classical Prescriptions

Progress in Sodium-glucose Co-transporter-2 Inhibitors: the New Target for Treatment of Type 2 Diabetes

Bulletin of 2008 Ruijin International Endocrinology Forum: Symposium on Diabetes and Cardiovascular Diseases

Bulletin of the 12th National Diabetes Congress of Chinese Medical Association Diabetes Society

Observational Study Evaluating the Effectiveness of Physician-Targeted Education for Improving Glycemic Management of Patients with Type 2 Diabetes (BEYOND II)

糖尿病的强化治疗策略——精细降糖、安全达标

Assessment for Effect of Hospital-Community-Integrated Treatment and Management on Type Ⅱ Diabetes Patients

PDG8 EFFICACY OF PHARMACOLOGICAL MONOTHERAPIES FOR TYPE 2 DIABETES IN CHINA

PP93 Efficacy of Pharmacological Treatments for Type 2 Diabetes in China

Integrated Intervention in Management of Type 2 Diabetes

Evaluation on effects of community management on 1 671 patients with type 2 diabetes mellitus in Shanghai

Effects of Community-Based Dietary Intervention on Type 2 Diabetes Mellitus

Standards of Care for Type 2 Diabetes in China

Study of Management of Type 2 Diabetes in Community

Blood glucose control and self-behavioral management of patients with Type 2 diabetes melli-tus (T2DM) in Shanghai communities

The Impact of Intervention with "insulin Therapy Management Unit" Program in Poorly Controlled Type 2 Diabetes in a Community of Shanghai

REVIEW OF THE 68TH SHUANGQING FORUM ENTITLED "THE KEY SCIENTIFIC QUESTIONS ON PATHOGENESIS AND INTERVENTION OF DIABETES IN CHINA"